CURATE.AI Optimized Modulation for Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

Phenotypic Personalized Medicine: Systematically Optimized Combination Therapy in Multiple Myeloma Using CURATE.AI

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03759093
• Other study ID #: 2015/00280
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: September 10, 2023
• Est. completion date: September 10, 2025

Study information

• Verified date: August 2023
• Source: National University Hospital, Singapore
• Contact: Wee Joo Chng, Prof
• Phone: 67795555
• Email: mdccwj[@]nus.edu.sg
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Clinical trial applying CURATE.AI, a Phenotypic Precision Medicine (PPM) platform, to Bortezomib, Thalidomide, Cyclophosphamide and Lenalidomide dosing in multiple myeloma patients to show improvement in response.

Description:

In conventional combination chemotherapy, drug doses are typically determined using dose escalation to reach a maximum tolerated dose (MTD) or via dose expansion to identify suitable regimen administration guideline, and the combinations are subsequently administered at fixed doses. During the course of treatment, the patient's response to therapy evolves and changes due to the time-dependent, dose dependent, and patient-specific nature of drug synergy and resulting efficacy and tolerability. To overcome this challenge, we have developed CURATE.AI, a Phenotypic Precision Medicine (PPM) platform, which has been clinically validated and used to prospectively optimize patient liver transplant immunosuppression, and tuberculosis therapy, among other indications. In this study, CURATE.AI may improve patient response by providing dose recommendations for Bortezomib, Thalidomide, Cyclophosphamide and Lenalidomide to the clinical team over the course of the patient's treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: September 10, 2025
• Est. primary completion date: September 10, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 99 Years

Eligibility

Inclusion Criteria:

1. Multiple myeloma diagnosed according to standard criteria, without prior anti-myeloma treatment at study entry. Both transplant eligible and ineligible patients may be included.

2. Patients must have evaluable multiple myeloma with at least one of the following (within 21 days of starting treatment)

1. Serum M-protein = 0.5g/dL, or

2. In subjects without detectable serum M-protein, Urine M-protein = 200mg/24 hour, or serum free light chai (sFLC) > 100mg/L (involved light chain) and an abnormal kappa/Lambda ratio

3. Males and females = 18 years of age or > country's legal age for adult consent

4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2

5. Patients must meet the following clinical laboratory criteria with 21 days of starting

treatment:

1. Absolute neutrophil count (ANC) = 1,000/mm3 and platelet = 50,000/mm3 (= 30,000/mm3 if myeloma involvement in the bone marrow is >50%)

2. Total bilirubin = 1.5 x the upper limit of the normal range (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 x ULN.

3. Calculated creatinine clearance = 30mL/min or creatinine < 3mg/dL.

6. Written informed consent in accordance with federal, local and institutional guidelines

Exclusion Criteria:

1. Female patients who are lactating or pregnant

2. Multiple Myeloma of IgM subtype

3. Glucocorticoid therapy (prednisolone > 30mg/day or equivalent) within 14 days prior to informed consent obtained

4. POEMS syndrome

5. Plasma cell leukaemia or circulating plasma cells = 2 x 109/L

6. Waldenstrom's Macroglobulinaemia

7. Patients with known amyloidosis

8. Chemotherapy with approved or investigation anticancer therapeutics within 21 days prior to starting bortezomib treatment

9. Focal radiation therapy within 7 days prior to start of treatment. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to start of treatment

10. Immunotherapy (excluding steroids) 21 days prior to start of treatment

11. Major surgery (excluding kyphoplasty) within 28 days prior to start of treatment

12. Active congestive heart failure (New York Heart Association [NYHA] Class III or IV), symptomatic ischaemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within 4 months prior to informed consent obtained

13. Known HIV seropositive, hepatitis C infection, and/or hepatitis B (except for patients with hepatitis B surface antigen or core antibody receiving and responding to antiviral therapy directed at hepatitis B: these patients are allowed)

14. Patients with known cirrhosis

15. Second malignancy within the past 3 years except:

1. Adequately treated basal cell or squamous cell skin cancer

2. Carcinoma in situ of the cervix

3. Breast carcinoma in situ with full surgical resection

16. Patients with myelodysplastic syndrome

17. Patients with steroid, cyclophosphamide, bortezomib, lenalidomide or thalidomide hypersensitivity

18. Patients with a calculated creatinine clearance less than 30ml/min by the Cockroft Galt method.

19. Prior treatment with Bortezomib

20. Contraindication to any of the required concomitant drugs or supportive treatments

21. Any clinically significant medical disease or psychiatric condition that, in the investigator's opinion, may interfere with protocol

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Bortezomib
Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
• Cyclophosphamide
Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
• Dexamethasone
Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team

Other:
• CURATE.AI-Guided dosage modulation
CURATE.AI-guided modulation of Velcade and Cyclophosphamide dosages for VCD regimen, Velcade and Thalidomide dosages for VTD regimen, and Velcade and Lenalidomide dosages for VRD regimen

Drug:
• Thalidomide
Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
• Bortezomib
Dose in a range of 0.7,1.0,1.3 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined and guided by CURATE.AI and approved by the clinical care team
• Cyclophosphamide
Dosing in a range of 100, 300, 500 mg PO on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
• Thalidomide
Dose in a range of 50-200mg PO on day 1-28 for cycles 1 to 4 as determined and guided by CURATE.AI and approved by the clinical care team.
• Dexamethasone
40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team according to standard of care
• Lenalidomide
Standard dosing based on product insert and subjected to dose adjustments as determined by clinical care team
• Lenalidomide
Dose in a range of 5-25mg PO on day 1-21 for cycles 1 to 4, as determined and guided by CURATE.AI and approved by the clinical care team.

Locations

Country	Name	City	State
Singapore	National University Hospital	Singapore

Sponsors (2)

Lead Sponsor	Collaborator
National University Hospital, Singapore	National University of Singapore

Country where clinical trial is conducted

Singapore, 

References & Publications (1)

Pantuck, A.J., Lee, D.K., Kee, T., Wang, P., Lakhotia, S., Silverman, M.H., Mathis, C., Drakaki, A., Belldegrun, A.S., Ho, C.M. and Ho, D., 2018. Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE. AI, an Artificial Intelligence Platform. Advanced Therapeutics, 1(6), p.1800104.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate	Complete response (CR), or stringent complete response (sCR), or very good partial response (VGPR), or partial response (PR) based on IMWG criteria at the end of cycle 4	Up to 16 weeks or at the end of cycle 4 of treatment (each cycle is 28 days)
Secondary	Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)	Occurrence of adverse events throughout the study, graded via Common Terminology Criteria for Adverse Events (CTCAE) v 4.03 criteria.	Up to 16 weeks or at the end of cycle 4 of treatment (each cycle is 28 days)